FDA Approves Entadfi (finasteride and tadalafil) as a New Treatment for Benign Prostatic Hyperplasia
MIAMI, Dec. 13, 2021 (GLOBE NEWSWIRE)— Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, announced today that the U.S. Food and Drug...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Benign Prostatic Hyperplasia | Cancer | Cancer & Oncology | Cialis | Drugs & Pharmacology | Propecia | Prostate Cancer